Trial · NCT06778434
The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans
NCT06778434, Phase 2, Recruiting, VA Office of Research and Development
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans. Trials, record NCT06778434. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06778434
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans
- NCT number
- NCT06778434
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 48 participants, estimated
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Actinic Keratosis, Imipramine, Photodynamic Therapy
- Interventions
- Imipramine, Control Vehicle
- First posted
- 2025-01-16
- Last updated
- 2025-12-22
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | (Forearm Arm Only): Difference in areas of Candida antigen skin test results with PDT+ imipramine | 7, 30, 90 days post-PDT treatments | Size of skin reactions from baseline values will be obtained following PDT + vehicle/imipramine using calipers. |
| Primary | (Forearm Arm Only): Difference in redness of Candida antigen skin test results with PDT+ imipramine | 7, 30, 90 days post-PDT treatments | Redness of skin reactions from baseline values will be obtained following PDT + vehicle/imipramine using mexameter device and thermal imaging. |
| Primary | Difference in numbers of precancerous AK skin lesions with PDT and imipramine on the face | 6, 12 months post-PDT treatment | Differences in baseline values of AK will be obtained following PDT + vehicle/imipramine by counting and mapping on each side of face/scalp. |
| Secondary | Difference in numbers of precancerous AK skin lesions with PDT and imipramine on the forearms | 6, 12 months post-PDT treatment | Differences in baseline values of AK will be obtained following PDT + vehicle/imipramine by counting and mapping each forearm/wrist. |
| Secondary | (Forearm Arm Only): Difference in gene profile of skin following treatment with PDT + imipramine | 7 days post-PDT treatment | Differences in transcriptome RNA values from baseline will be obtained following PDT + vehicle/impramine by use of tissue RNA-seq with a commercial dermal transcriptomal patch. |
| Secondary | Differences in post-PDT redness with PDT + imipramine | 10 min, 30 min, 24 hours post-PDT treatments | Differences in redness following PDT + imipramine vs PDT + vehicle from baseline values will be obtained using a mexameter device and thermal imaging on face/forearms. |
| Secondary | Differences in post-PDT pain with PDT + imipramine | 10 min, 30 min, 24 hours post-PDT treatments | Differences in pain following PDT + imipramine vs PDT + vehicle from baseline values will be obtained using a visual analog scale on face/forearms. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06778434
GET https://conductscience.org/api/trials/v1/NCT06778434/registered